CDT Equity Inc.
CDT Equity Inc. (CDT): 4 pipeline candidates · ~2 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.5 months
D/E -1.79 · 0% dilution
Lead: Preclinical
4 candidates
N/A
N/A
A transparent, data-derived signal for CDT Equity Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.4M
Cash
$1.5M
Quarterly Burn
$4.6M
Runway
1.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| AZD1656 | Preclinical |
| AZD1656 Cocrystal | — |
| AZD5658 | Preclinical |
| AZD5904 | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$10
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 2 | $10 |
Frequently asked questions
How many drug candidates are in CDT Equity Inc.'s pipeline?
CDT Equity Inc. (CDT) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CDT Equity Inc.'s lead drug candidate?
CDT Equity Inc.'s most advanced tracked candidate is AZD1656 (Preclinical) for Autoimmune disorders.
What is CDT Equity Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CDT Equity Inc. has approximately 1.5 months of cash runway.
What is CDT Equity Inc.'s market capitalization?
CDT Equity Inc.'s market capitalization is approximately $3.4M.
Who is the CEO of CDT Equity Inc.?
Dr. Andrew Regan is the chief executive officer of CDT Equity Inc. (CDT).
Get the full picture on CDT Equity Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.